Takeda is buying Adderall maker Shire for $64 billion in pharma's biggest deal of the year
Reuters
- Takeda has reached a deal to buy Adderall drugmaker Shire for $64.3 billion.
- The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda and Botox-maker Allergan.
- A transaction between Shire and Takeda is the largest pharma deal of the year.
Takeda has reached a preliminary agreement to buy Adderall drugmaker Shire for $64 billion in the largest pharma deal of the year.
The deal strengthens the Japanese drugmakers' footprint in the US, where Shire has a large presence, and also expands its position in rare diseases like hemophilia. See the rest of the story at Business Insider
NOW WATCH: The chief economist at a $163 billion firm dispels one of investing's biggest myths
See Also:
- You can tell someone's lying to you by watching their face — here are 12 dead giveaways
- 'Losing direction': Allergan investors are unhappy after a wild 4-hour takeover drama
- A bidding war for the maker of Adderall stalled out after just 4 hours
SEE ALSO: Frustrated investors want rare disease drugmaker Jazz to sell its blockbuster sleep business
DON'T MISS: 'Losing direction': Allergan investors are unhappy after a wild 4-hour takeover drama